ID   TENR_RAT                Reviewed;        1356 AA.
AC   Q05546;
DT   15-MAR-2005, integrated into UniProtKB/Swiss-Prot.
DT   01-NOV-1996, sequence version 1.
DT   24-JUL-2024, entry version 169.
DE   RecName: Full=Tenascin-R;
DE            Short=TN-R;
DE   AltName: Full=Janusin;
DE   AltName: Full=Neural recognition molecule J1-160/180;
DE   AltName: Full=Restrictin;
DE   Flags: Precursor;
GN   Name=Tnr;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS 1 AND 2), DEVELOPMENTAL STAGE, AND
RP   TISSUE SPECIFICITY.
RX   PubMed=7679676; DOI=10.1083/jcb.120.5.1237;
RA   Fuss B., Wintergerst E.-S., Bartsch U., Schachner M.;
RT   "Molecular characterization and in situ mRNA localization of the neural
RT   recognition molecule J1-160/180: a modular structure similar to tenascin.";
RL   J. Cell Biol. 120:1237-1249(1993).
RN   [2]
RP   INTERACTION WITH CNTN1.
RX   PubMed=9081628; DOI=10.1111/j.1460-9568.1996.tb01262.x;
RA   Xiao Z.-C., Taylor J., Montag D., Rougon G., Schachner M.;
RT   "Distinct effects of recombinant tenascin-R domains in neuronal cell
RT   functions and identification of the domain interacting with the neuronal
RT   recognition molecule F3/11.";
RL   Eur. J. Neurosci. 8:766-782(1996).
RN   [3]
RP   INTERACTION WITH BCAN.
RX   PubMed=9294172; DOI=10.1073/pnas.94.19.10116;
RA   Aspberg A., Miura R., Bourdoulous S., Shimonaka M., Heinegard D.,
RA   Schachner M., Ruoslahti E., Yamaguchi Y.;
RT   "The C-type lectin domains of lecticans, a family of aggregating
RT   chondroitin sulfate proteoglycans, bind tenascin-R by protein-protein
RT   interactions independent of carbohydrate moiety.";
RL   Proc. Natl. Acad. Sci. U.S.A. 94:10116-10121(1997).
RN   [4]
RP   INTERACTION WITH SCN2B, AND FUNCTION.
RX   PubMed=9861042; DOI=10.1073/pnas.95.26.15753;
RA   Srinivasan J., Schachner M., Catterall W.A.;
RT   "Interaction of voltage-gated sodium channels with the extracellular matrix
RT   molecules tenascin-C and tenascin-R.";
RL   Proc. Natl. Acad. Sci. U.S.A. 95:15753-15757(1998).
RN   [5]
RP   INTERACTION WITH PTPRZ1 AND CSPG3.
RX   PubMed=9507007; DOI=10.1074/jbc.273.12.6998;
RA   Milev P., Chiba A., Haring M., Rauvala H., Schachner M., Ranscht B.,
RA   Margolis R.K., Margolis R.U.;
RT   "High affinity binding and overlapping localization of neurocan and
RT   phosphacan/protein-tyrosine phosphatase-zeta/beta with tenascin-R,
RT   amphoterin, and the heparin-binding growth-associated molecule.";
RL   J. Biol. Chem. 273:6998-7005(1998).
RN   [6]
RP   GLYCOSYLATION, AND FUNCTION.
RX   PubMed=10723065;
RX   DOI=10.1002/(sici)1097-4547(20000401)60:1<21::aid-jnr3>3.0.co;2-h;
RA   Probstmeier R., Stichel C.C., Muller H.W., Asou H., Pesheva P.;
RT   "Chondroitin sulfates expressed on oligodendrocyte-derived tenascin-R are
RT   involved in neural cell recognition. Functional implications during CNS
RT   development and regeneration.";
RL   J. Neurosci. Res. 60:21-36(2000).
RN   [7]
RP   GLYCOSYLATION.
RX   PubMed=12393878; DOI=10.1074/jbc.m209876200;
RA   Woodworth A., Fiete D., Baenziger J.U.;
RT   "Spatial and temporal regulation of tenascin-R glycosylation in the
RT   cerebellum.";
RL   J. Biol. Chem. 277:50941-50947(2002).
RN   [8]
RP   GLYCOSYLATION, DEVELOPMENTAL STAGE, AND FUNCTION.
RX   PubMed=14681222; DOI=10.1074/jbc.m312466200;
RA   Woodworth A., Pesheva P., Fiete D., Baenziger J.U.;
RT   "Neuronal-specific synthesis and glycosylation of tenascin-R.";
RL   J. Biol. Chem. 279:10413-10421(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-723, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [10]
RP   GLYCOSYLATION [LARGE SCALE ANALYSIS] AT ASN-1259, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain;
RX   PubMed=24090084; DOI=10.1021/pr400783j;
RA   Parker B.L., Thaysen-Andersen M., Solis N., Scott N.E., Larsen M.R.,
RA   Graham M.E., Packer N.H., Cordwell S.J.;
RT   "Site-specific glycan-peptide analysis for determination of N-glycoproteome
RT   heterogeneity.";
RL   J. Proteome Res. 12:5791-5800(2013).
RN   [11]
RP   TISSUE SPECIFICITY, AND INDUCTION BY INJURY.
RX   PubMed=28270793; DOI=10.3389/fneur.2017.00049;
RA   Lindholm T., Risling M., Carlstedt T., Hammarberg H., Wallquist W.,
RA   Cullheim S., Skoeld M.K.;
RT   "Expression of Semaphorins, Neuropilins, VEGF, and Tenascins in Rat and
RT   Human Primary Sensory Neurons after a Dorsal Root Injury.";
RL   Front. Neurol. 8:49-49(2017).
RN   [12]
RP   X-RAY CRYSTALLOGRAPHY (2.6 ANGSTROMS) OF 489-771, AND INTERACTION WITH
RP   ACAN.
RX   PubMed=15296743; DOI=10.1016/j.str.2004.05.021;
RA   Lundell A., Olin A.I., Morgelin M., al-Karadaghi S., Aspberg A.,
RA   Logan D.T.;
RT   "Structural basis for interactions between tenascins and lectican C-type
RT   lectin domains: evidence for a crosslinking role for tenascins.";
RL   Structure 12:1495-1506(2004).
CC   -!- FUNCTION: Neural extracellular matrix (ECM) protein involved in
CC       interactions with different cells and matrix components. Theses
CC       interactions can influence cellular behavior by either evoking a stable
CC       adhesion and differentiation, or repulsion and inhibition of neurite
CC       growth. Binding to cell surface gangliosides inhibits RGD-dependent
CC       integrin-mediated cell adhesion and results in an inhibition of
CC       PTK2/FAK1 (FAK) phosphorylation and cell detachment. Binding to
CC       membrane surface sulfatides results in a oligodendrocyte adhesion and
CC       differentiation. Interaction with CNTN1 induces a repulsion of neurons
CC       and an inhibition of neurite outgrowth. Interacts with SCN2B may play a
CC       crucial role in clustering and regulation of activity of sodium
CC       channels at nodes of Ranvier. TNR-linked chondroitin sulfate
CC       glycosaminoglycans are involved in the interaction with FN1 and
CC       mediates inhibition of cell adhesion and neurite outgrowth. The highly
CC       regulated addition of sulfated carbohydrate structure may modulate the
CC       adhesive properties of TNR over the course of development and during
CC       synapse maintenance (By similarity). {ECO:0000250,
CC       ECO:0000269|PubMed:10723065, ECO:0000269|PubMed:14681222,
CC       ECO:0000269|PubMed:9861042}.
CC   -!- SUBUNIT: Forms oligomers. Interacts with TNC and FN1 (By similarity).
CC       Interacts with BCAN and ACAN in a calcium -dependent manner. Interacts
CC       with CNTN1, SCN2B, PTPRZ1, and CSPG3. {ECO:0000250,
CC       ECO:0000269|PubMed:15296743, ECO:0000269|PubMed:9081628,
CC       ECO:0000269|PubMed:9294172, ECO:0000269|PubMed:9507007,
CC       ECO:0000269|PubMed:9861042}.
CC   -!- SUBCELLULAR LOCATION: Secreted, extracellular space, extracellular
CC       matrix.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1; Synonyms=TN-R 180, 180 kDa form;
CC         IsoId=Q05546-1; Sequence=Displayed;
CC       Name=2; Synonyms=TN-R 160, 160 kDa form;
CC         IsoId=Q05546-2; Sequence=VSP_012995;
CC   -!- TISSUE SPECIFICITY: Brain-specific (PubMed:7679676). Expressed in
CC       oligodendrocytes and small subsets of neurons (mainly interneurons and
CC       motoneurons) of the cerebellum, hippocampus and olfactory bulb
CC       (PubMed:7679676). Expressed in dorsal root ganglia (PubMed:28270793).
CC       {ECO:0000269|PubMed:28270793, ECO:0000269|PubMed:7679676}.
CC   -!- DEVELOPMENTAL STAGE: Expression in oligodendrocytes is highest between
CC       the second and third postnatal week and low in the adult. In contrast
CC       the expression in neurons increases from birth to third postnatal week
CC       and is continuous from late development to adulthood. Isoform 1 is the
CC       dominant form early in development. Isoform 2 is more prominent later
CC       in development and in adulthood. {ECO:0000269|PubMed:14681222,
CC       ECO:0000269|PubMed:7679676}.
CC   -!- INDUCTION: Transiently increased in dorsal root ganglia 1 day post-
CC       dorsal rhizotomy, returning to comparable levels 3 days post-injury
CC       (PubMed:28270793). Increased in dorsal root ganglia in response to both
CC       sciatic nerve crush and transection injury (PubMed:28270793).
CC       {ECO:0000269|PubMed:28270793}.
CC   -!- DOMAIN: The EGF-like domains mediate interaction with CNTN1. The
CC       fibronectin type-III domains 3-5 mediate interaction with BCAN. The
CC       fibronectin type-III domains 1-2 and 7-9 mediate interaction with
CC       SCN2B.
CC   -!- PTM: Contains N-linked oligosaccharides, O-linked sialylated structures
CC       (By similarity). Contains O-linked chondroitin sulfate
CC       glycosaminoglycans. Contains N-linked oligosaccharides with a sulfated
CC       carbohydrate structure type GalNAc-4-SO4 or HNK-1 (SO4-3-
CC       GlcUABeta1,3GalBeta1,4GlcNAc). The levels of HNK-1 rise and fall in
CC       parallel to those of TNR during postnatal development of the
CC       cerebellum. In contrast, levels of GalNAc-4-SO4 are regulated
CC       independently from those of TNR, rising late in cerebellar development
CC       and continuing into adulthood. Early in postnatal development, GalNAc-
CC       4-SO4 is found predominantly on isoform 1, whereas in the adult it is
CC       predominantly on isoform 2. {ECO:0000250, ECO:0000269|PubMed:10723065,
CC       ECO:0000269|PubMed:12393878, ECO:0000269|PubMed:14681222}.
CC   -!- SIMILARITY: Belongs to the tenascin family. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; Z18630; CAA79229.1; -; mRNA.
DR   PIR; A45445; A45445.
DR   RefSeq; NP_037177.1; NM_013045.1.
DR   PDB; 1TDQ; X-ray; 2.60 A; A=502-771.
DR   PDBsum; 1TDQ; -.
DR   AlphaFoldDB; Q05546; -.
DR   SMR; Q05546; -.
DR   BioGRID; 247598; 2.
DR   IntAct; Q05546; 2.
DR   MINT; Q05546; -.
DR   STRING; 10116.ENSRNOP00000068101; -.
DR   GlyCosmos; Q05546; 13 sites, 3 glycans.
DR   GlyGen; Q05546; 16 sites, 3 N-linked glycans (1 site).
DR   iPTMnet; Q05546; -.
DR   PhosphoSitePlus; Q05546; -.
DR   PaxDb; 10116-ENSRNOP00000068101; -.
DR   GeneID; 25567; -.
DR   KEGG; rno:25567; -.
DR   AGR; RGD:3886; -.
DR   CTD; 7143; -.
DR   RGD; 3886; Tnr.
DR   eggNOG; KOG1225; Eukaryota.
DR   eggNOG; KOG2579; Eukaryota.
DR   InParanoid; Q05546; -.
DR   OrthoDB; 5489847at2759; -.
DR   PhylomeDB; Q05546; -.
DR   Reactome; R-RNO-3000178; ECM proteoglycans.
DR   EvolutionaryTrace; Q05546; -.
DR   PRO; PR:Q05546; -.
DR   Proteomes; UP000002494; Unplaced.
DR   GO; GO:0009986; C:cell surface; ISO:RGD.
DR   GO; GO:0062023; C:collagen-containing extracellular matrix; ISO:RGD.
DR   GO; GO:0031012; C:extracellular matrix; ISO:RGD.
DR   GO; GO:0005615; C:extracellular space; IBA:GO_Central.
DR   GO; GO:0098978; C:glutamatergic synapse; ISO:RGD.
DR   GO; GO:0098686; C:hippocampal mossy fiber to CA3 synapse; IDA:SynGO.
DR   GO; GO:0045121; C:membrane raft; ISO:RGD.
DR   GO; GO:0072534; C:perineuronal net; ISO:RGD.
DR   GO; GO:0098966; C:perisynaptic extracellular matrix; IDA:SynGO.
DR   GO; GO:0098685; C:Schaffer collateral - CA1 synapse; ISO:RGD.
DR   GO; GO:0090733; C:tenascin complex; ISO:RGD.
DR   GO; GO:0005178; F:integrin binding; IPI:RGD.
DR   GO; GO:0008306; P:associative learning; ISO:RGD.
DR   GO; GO:0048675; P:axon extension; ISO:RGD.
DR   GO; GO:0048677; P:axon extension involved in regeneration; ISO:RGD.
DR   GO; GO:0030198; P:extracellular matrix organization; ISO:RGD.
DR   GO; GO:0035641; P:locomotory exploration behavior; ISO:RGD.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0050804; P:modulation of chemical synaptic transmission; ISO:RGD.
DR   GO; GO:0030517; P:negative regulation of axon extension; ISO:RGD.
DR   GO; GO:0048692; P:negative regulation of axon extension involved in regeneration; ISO:RGD.
DR   GO; GO:0007162; P:negative regulation of cell adhesion; IDA:RGD.
DR   GO; GO:0022408; P:negative regulation of cell-cell adhesion; ISO:RGD.
DR   GO; GO:0010977; P:negative regulation of neuron projection development; ISO:RGD.
DR   GO; GO:0050805; P:negative regulation of synaptic transmission; ISO:RGD.
DR   GO; GO:0007399; P:nervous system development; TAS:RGD.
DR   GO; GO:0097402; P:neuroblast migration; ISO:RGD.
DR   GO; GO:0050885; P:neuromuscular process controlling balance; ISO:RGD.
DR   GO; GO:0007158; P:neuron cell-cell adhesion; ISO:RGD.
DR   GO; GO:0051968; P:positive regulation of synaptic transmission, glutamatergic; ISO:RGD.
DR   GO; GO:0051971; P:positive regulation of transmission of nerve impulse; ISO:RGD.
DR   GO; GO:0030155; P:regulation of cell adhesion; ISO:RGD.
DR   GO; GO:0045595; P:regulation of cell differentiation; ISO:RGD.
DR   GO; GO:0030334; P:regulation of cell migration; ISO:RGD.
DR   GO; GO:0050808; P:synapse organization; ISO:RGD.
DR   GO; GO:0035249; P:synaptic transmission, glutamatergic; ISO:RGD.
DR   GO; GO:0022029; P:telencephalon cell migration; ISO:RGD.
DR   CDD; cd00063; FN3; 9.
DR   CDD; cd00087; FReD; 1.
DR   Gene3D; 3.90.215.10; Gamma Fibrinogen, chain A, domain 1; 1.
DR   Gene3D; 2.60.40.10; Immunoglobulins; 9.
DR   Gene3D; 2.10.25.10; Laminin; 4.
DR   InterPro; IPR050991; ECM_Regulatory_Proteins.
DR   InterPro; IPR000742; EGF-like_dom.
DR   InterPro; IPR013111; EGF_extracell.
DR   InterPro; IPR041161; EGF_Tenascin.
DR   InterPro; IPR036056; Fibrinogen-like_C.
DR   InterPro; IPR014716; Fibrinogen_a/b/g_C_1.
DR   InterPro; IPR002181; Fibrinogen_a/b/g_C_dom.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   NCBIfam; NF040941; GGGWT_bact; 1.
DR   PANTHER; PTHR46708; TENASCIN; 1.
DR   PANTHER; PTHR46708:SF6; TENASCIN-R; 1.
DR   Pfam; PF07974; EGF_2; 1.
DR   Pfam; PF18720; EGF_Tenascin; 3.
DR   Pfam; PF00147; Fibrinogen_C; 1.
DR   Pfam; PF00041; fn3; 9.
DR   SMART; SM00181; EGF; 4.
DR   SMART; SM00186; FBG; 1.
DR   SMART; SM00060; FN3; 9.
DR   SUPFAM; SSF56496; Fibrinogen C-terminal domain-like; 1.
DR   SUPFAM; SSF49265; Fibronectin type III; 5.
DR   PROSITE; PS00022; EGF_1; 5.
DR   PROSITE; PS01186; EGF_2; 4.
DR   PROSITE; PS51406; FIBRINOGEN_C_2; 1.
DR   PROSITE; PS50853; FN3; 9.
PE   1: Evidence at protein level;
KW   3D-structure; Alternative splicing; Cell adhesion; Coiled coil;
KW   Disulfide bond; EGF-like domain; Extracellular matrix; Glycoprotein;
KW   Phosphoprotein; Proteoglycan; Reference proteome; Repeat; Secreted;
KW   Sialic acid; Signal.
FT   SIGNAL          1..31
FT                   /evidence="ECO:0000255"
FT   CHAIN           32..1356
FT                   /note="Tenascin-R"
FT                   /id="PRO_0000007749"
FT   DOMAIN          188..199
FT                   /note="EGF-like 1"
FT   DOMAIN          204..230
FT                   /note="EGF-like 2"
FT   DOMAIN          235..261
FT                   /note="EGF-like 3"
FT   DOMAIN          281..292
FT                   /note="EGF-like 4"
FT   DOMAIN          293..324
FT                   /note="EGF-like 5"
FT   DOMAIN          328..419
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          420..504
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          505..596
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          597..686
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          687..776
FT                   /note="Fibronectin type-III 5"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          777..864
FT                   /note="Fibronectin type-III 6"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          865..953
FT                   /note="Fibronectin type-III 7"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          954..1040
FT                   /note="Fibronectin type-III 8"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1041..1129
FT                   /note="Fibronectin type-III 9"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          1127..1342
FT                   /note="Fibrinogen C-terminal"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   COILED          127..157
FT                   /evidence="ECO:0000255"
FT   MOD_RES         723
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   CARBOHYD        55
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        176
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        180
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        198
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        271
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        278
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        302
FT                   /note="O-linked (Xyl...) (chondroitin sulfate) serine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        391
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        469
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        580
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        790
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        868
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        873
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1034
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1044
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        1259
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0007744|PubMed:24090084"
FT   DISULFID        297..307
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   DISULFID        314..323
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00739"
FT   VAR_SEQ         772..861
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:7679676"
FT                   /id="VSP_012995"
FT   STRAND          507..514
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          519..524
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          531..543
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          547..551
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          556..560
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          568..577
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          585..590
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          597..604
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          609..614
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          621..629
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          636..641
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          644..652
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          660..669
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          677..682
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          689..696
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          701..706
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          713..720
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          722..724
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          727..734
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          736..740
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          749..757
FT                   /evidence="ECO:0007829|PDB:1TDQ"
FT   STRAND          765..769
FT                   /evidence="ECO:0007829|PDB:1TDQ"
SQ   SEQUENCE   1356 AA;  149371 MW;  9BFE2BF7AD4CA781 CRC64;
     MGIEGETVVL KNMLIGVNLI LLGSMLKPSE CRLEVTTERV QRQTVEEEGG ASSYNTSSKE
     QPMVFNHVYN INVPLESLCS SGLEASAEQD VSAEDDTLAE YTGQTSDHES QVTFTHKINL
     PKKACPCASS AQVLQELLSR IEMLEREVSV LRDQCNTNCC QESAATGQLD YVPHCSGHGN
     FSFESCGCIC NEGWFGKNCS EPYCPLGCSS RGVCVDGQCI CDSEYSGDDC SELRCPTDCS
     SRGLCVDGEC VCEEPYTGED CRELRCPGDC SGKGQCANGT CLCQEGYAGE DCSQRRCLNA
     CSGRGHCQEG LCICEEGYQG PDCSAVTPPE DLRVAGISDR SIELEWDGPM AVTEYVISYQ
     PSLGGLQLQQ RVPGDWSGVT ITELEPGLTY NISVYAVISN ILSLPITAKV ATHLSTPQGL
     QFKTITETTV EVQWEPFSFS FDGWEISFTP KNNEGGVIAQ LPSDVTSFNQ TGLKPGEEYI
     VNVVALKEQA RGPPTSASVS TVIDGPTQIL VRDVSDTVAF VEWTPPRAKV DFILLKYGLV
     GGEGGKTTFR LQPPLSQYSV QALRPGSRYE VSISAVRGTN ESDASSTQFT TEIDAPKNLR
     VGSRTATSLD LEWDNSEAEA QEYKVVYSTL AGEQYHEVLV PKGIGPTTKT TLTDLVPGTE
     YGVGISAVMN SKQSIPATMN ARTELDSPRD LMVTASSETS ISLIWTKASG PIDHYRITFT
     PSSGISSEVT VPRDRTSYTL TDLEPGAEYI ISITAERGRQ QSLESTVDAF TGFRPISHLH
     FSHVTSSSVN ITWSDPSPPA DRLILNYSPR DEEEEMMEVL LDATKRHAVL MGLQPATEYI
     VNLVAVHGTV TSEPIVGSIT TGIDPPKNIT ISNVTKDSLT VSWSPPVAPF DYYEYPIDHP
     SGRLDSSVVP NTVTEFTITR LYPASQYEIS LNSVRGREES ERICTLVHTA MDSPMDLIAT
     NITPTEALLQ WKAPMGEVEN YVIVLTHFAM AGETILVDGV SEEFQLVDLL PRTHYTVTMY
     ATSGPLVSGT IATNFSTLLD PPANLTASEV TRQSALISWQ PPRAAIENYV LTYKSTDGSR
     KELIVDAEDT WIRLEGLSEN TDYTVLLQAA QEATRSSLTS TIFTTGGRVF SHPQDCAQHL
     MNGDTLSGVY TIFLNGELSH KLQVYCDMTT DGGGWIVFQR RQNGQTDFFR KWADYRVGFG
     NLEDEFWLGL DNYHRITAQG RYELRVDMRD GQEAVFAYYD KFAVEDSRSL YKLRIGGYNG
     TAGDSLSYHQ GRPFSTEDRD NDVAVTNCAM SYKGAWWYKN CHRTNLNGKY GESRHSQGIN
     WYHWKGHEFS IPFVEMKMRP YIHRLTAGRK RRALKF
//
